An mRNA-based vaccine trains the immune system to recognize and initiate humoral and T-cell-mediated immunity against cancer-specific antigens.352 While this concept of a “personalized vaccine” was initially explored in patients with melanoma,353,354 it offers a platform to generate epitope-directed vaccines, including KRAS epitopes. The gene discussed is KRAS; the disease is melanoma.